Complete dosing information for NATALIZUMAB-SZTN
Medical guidance required: Dosing information here is for educational purposes. Your healthcare provider will determine the appropriate dose based on your specific condition, kidney function, other medications, and medical history. Never adjust your dose without consulting your doctor or pharmacist.
2 DOSAGE AND ADMINISTRATION • 300 mg infused intravenously over one hour, every four weeks. Do not give as an intravenous push or bolus. ( 2.1 , 2.2 ) • TYRUKO solution must be administered within 4 hours of preparation. ( 2.3 ) • Observe patients during all infusions. Post-infusion, for the first 12 infusions, observe patients for one hour after the infusion is complete. For patients who have received 12 infusions without evidence of a hypersensitivity reaction, observe patients post-infusion for the 13th and subsequent infusions according to clinical judgment. ( 2.4 ) • In CD, discontinue in patients that have not experienced therapeutic benefit by 12 weeks of induction therapy, and in patients that cannot discontinue chronic concomitant steroids within six months of starting therapy. ( 2.2 ) 2.1 Multiple Sclerosis (MS) Only prescribers registered in the MS TYRUKO REMS Program may prescribe TYRUKO for multiple sclerosis [see Warnings and Precautions ( 5.2 )] . The recommended dose of